Compare Boston Scientific Corporation (BSX) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Oatly Group AB - ADR — how do they compare? Boston Scientific Corporation trades at $51.55 (market cap $74.19B), while Oatly Group AB - ADR trades at $13.24 (market cap $415.98M). The key difference: Boston Scientific Corporation is far larger — about 178.3× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | OTLY | |
|---|---|---|
Market Cap | $74.19B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $18.54 |
52-Week Low | $42.63 | $8.03 |
Enterprise Value | $86.27B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
OTLY trades at $13.18, up 0.46% on the day, with a bullish technical signal driven by moving averages and oversold RSI conditions. Revenue growth is accelerating, with Q2 2026 sales reaching $240.1 million and full-year guidance raised, though the company remains unprofitable with a net margin of -13.81%. Cash flow trends show reduced operational losses, but negative free cash flow persists.
The outlook hinges on OTLY's path to profitability; improved gross margins and cost controls offer potential upside, but high debt and sustained cash burn pose significant risks. Analyst sentiment is mixed with a 44.44% buy rating, reflecting optimism for growth against financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
